Related Experiment Video
Updated: Jun 18, 2026

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
Published on: September 5, 2016
Delivering antiviral siRNA into human T-cells: New approaches in RNAi-based HIV therapy
Hong-Seok Ban1, Sang-Kyung K Lee, Priti Kumar
1Hanyang University, Department of Bioengineering, 17 Haengdang-dong Seongdong-gu, Seoul 133-797, South Korea.
Abstract:
The ability to block the expression of any disease-causing gene or disease-related protein highlights the potential use of RNAi technology in the therapy of 'undruggable' human diseases. However, considering the risks associated with RNAi therapy, targeting and restricting the action of siRNA to specific cells could greatly minimize toxic side effects. However, this is a major challenge, as many primary cell types are highly recalcitrant to siRNA uptake. This review discusses advances in siRNA targeting methods for human T-cells, with an emphasis on the potential use of an RNAi-based therapy for the treatment of HIV/AIDS.
Related Concept Videos
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Inhibitors of Viral Protein Synthesis
Retrovirus Life Cycles
Antiviral Nucleoside Inhibitors
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...

